| (Values in U.S. Thousands) | Jun, 2022 | Mar, 2022 | Sep, 2022 | Jun, 2022 | Mar, 2022 |
| Sales | 470 | 310 | 690 | 1,100 | 330 |
| Sales Growth | +51.61% | -55.07% | -37.27% | +233.33% | unch |
| Net Income | -4,870 | -2,310 | -4,730 | -4,400 | -4,430 |
| Net Income Growth | -110.82% | +51.16% | -7.50% | +0.68% | unch |
Fresh2 Group Limited American ADR (FRES)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fresh2 Group Limited is a biotechnology company focused on early cancer screening and detection. The Company is also entering the business-to-business e-commerce food business with the formation of its wholly-owned subsidiary Fresh2 Technology Inc and the acquisition of Fresh2 Ecommerce Inc. Fresh2 Group Limited, formerly known as AnPac Bio-Medical Science Co. Ltd., is based in NEW YORK.
Fiscal Year End Date: 12/31